Vis enkel innførsel

dc.contributor.authorLobie, Tekle Airgecho
dc.contributor.authorRoba, Aklilu Abrham
dc.contributor.authorBooth, James
dc.contributor.authorKristiansen, Knut Ivan
dc.contributor.authorAseffa, Abraham
dc.contributor.authorSkarstad, Kirsten Jane
dc.contributor.authorBjørås, Magnar
dc.date.accessioned2022-02-17T10:23:13Z
dc.date.available2022-02-17T10:23:13Z
dc.date.created2022-02-16T12:49:23Z
dc.date.issued2021
dc.identifier.citationInternational Journal of Infectious Diseases. 2021, 111, 322-325.en_US
dc.identifier.issn1201-9712
dc.identifier.urihttps://hdl.handle.net/11250/2979629
dc.description.abstractMicrobe exposure to pharmaceutical and non-pharmaceutical agents plays a role in the development of antibiotic resistance. The risks and consequences associated with extensive disinfectant use during the COVID-19 pandemic remain unclear. Some disinfectants, like sanitizers, contain genotoxic chemicals that damage microbial DNA, like phenol and hydrogen peroxide. This damage activates error-prone DNA repair enzymes, which can lead to mutations that induce antimicrobial resistance. Public health priority programs that have faced drug-resistance challenges associated with diseases, such as tuberculosis, HIV, and malaria, have given less attention to risks attributable to the COVID-19 pandemic. Pathogen-specific programs, like the directly observed treatment strategy designed to fight resistance against anti-tuberculosis drugs, have become impractical because COVID-19 restrictions have limited in-person visits to health institutions. Here, we summarized the key findings of studies on the current state of antimicrobial resistance development from the perspective of current disinfectant use. Additionally, we provide a brief overview of the consequences of restricted access to health services due to COVID-19 precautions and their implications on drug resistance development.en_US
dc.language.isoengen_US
dc.publisherElsevier Ltd.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAntimicrobial resistance: A challenge awaiting the post-COVID-19 eraen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber322-325en_US
dc.source.volume111en_US
dc.source.journalInternational Journal of Infectious Diseasesen_US
dc.identifier.doi10.1016/j.ijid.2021.09.003
dc.identifier.cristin2002335
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal